Research
Mixed
Orlistat is generally not recommended for people living with HIV on combined antiretroviral therapy (cART) due to the risk of reduced absorption of antiretroviral drugs and subsequent loss of viral control.
Do not take Orlistat if you are on HIV medication without explicit approval from your doctor. It can block the absorption of your HIV drugs, causing your viral load to rise. There are safer alternatives available.
ModerateRefutesMEDIUM confidence
Given the significant risk associated with compromised control of HIV viremia, the absence of efficacy data in HIV patients, and the availability of alternative weight-loss agents suitable for PLWH, orlistat is generally not recommended in all HIV patients currently taking cART.
Why this rating
Based on pharmacokinetic principles and case reports linking initiation to loss of viral control, but lacks large-scale efficacy/safety trials in PLWH.
Source
HIV Treatment and Obesity: What’s New?
Paula Freitas et al. · Infectious diseases · 2023
DOI 10.5772/intechopen.112667
book_chapterCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Integrase strand transfer inhibitors (INSTIs), particularly dolutegravir and bictegravir, cause significant weight gain and treatment-emergent obesity in people living with HIV, with effects most pronounced in women and Black individuals.Good
- GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual agonists (Tirzepatide) are viable and promising options for weight loss in people living with HIV, with minimal drug-drug interaction risks compared to Orlistat.Moderate
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →